Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
复制标题
对氟达拉滨单药治疗的慢性淋巴细胞白血病患者进行长期随访。
作者：
M. Keating;S. O'brien;H. Kantarjian;W. Plunkett;E. Estey;C. Koller;M. Beran;E. Freireich
对113例慢性淋巴细胞白血病患者进行了氟达拉滨单药治疗后至少3年随访的临床反应和生存率进行了评价。78名患者既往接受过治疗，35名患者未经治疗。对治疗的反应和生存率与既往治疗的程度、疾病的分期以及患者是否对烷化剂难治密切相关。与生存相关的其他特征是患者的年龄和治疗开始时的血清白蛋白水平。未接受过既往治疗的缓解者的中位至进展时间为33个月，既往治疗患者为21个月。疾病进展后的生存率也与既往治疗的程度密切相关。对于烷化剂难治的患者，初始氟达拉滨治疗后没有成功的挽救方案，尽管氟达拉滨在接受氟达拉滨作为初始治疗或烷化剂不难治的患者中实现了进一步缓解。氟达拉滨停药后未维持缓解患者的发病率较低，每患者年感染风险小于1次。在此期间的发病率与临床反应和患者是否接受过既往治疗相关。虽然氟达拉滨是一种非常有效的细胞减灭方案，但大多数患者，包括那些真正完全缓解的患者，都会复发。在显示氟达拉滨对生存率的影响之前，需要更长时间的随访和比较试验。
The clinical response and survival of 113 patients with at least 3-year follow-up after treatment with fludarabine as a single agent for chronic lymphocytic leukemia has been evaluated. Seventy-eight patients were previously treated and 35 were untreated. The response to therapy and survival were strongly correlated with the degree of previous therapy, the stage of disease, and whether or not the patients were refractory to alkylating agents. Other characteristics associated with survival were the age of the patient and the serum albumin level at the start of therapy. The median time to progression of responders who had not received prior therapy was 33 months and was 21 months for previously treated patients. Survival after progression of disease was also strongly correlated with the degree of prior therapy. No successful salvage regimen after initial fludarabine therapy was shown for patients refractory to alkylating agents, although fludarabine achieved further remissions in patients who had received fludarabine as their initial treatment or were not refractory to alkylating agents. The morbidity of patients in unmaintained remission on discontinuation of fludarabine was low, with less than one episode of infection per patient-year at risk. The morbidity during this time was correlated with clinical response and whether the patients had received prior therapy. Although fludarabine is a very effective cytoreductive regimen, most patients, including those who achieved true complete remissions, will have recurrent disease. Longer follow-up and comparative trials are required before the effect of fludarabine on survival is shown.
登录
查看更多内容
9-β-D-阿拉伯呋喃糖基-2-氟腺嘌呤 5-单磷酸治疗非霍奇金淋巴瘤的 II 期试验：与脱氧胞苷激酶活性的反应的前瞻性比较。
影响因子：
11.2
作者：
Leiby,JM;Snider,KM;Kraut,EH;Metz,EN;Malspeis,L;Grever,MR
通讯作者：
Grever,MR
氟达拉滨：一种对慢性淋巴细胞白血病具有主要活性的新药。
影响因子：
20.3
作者：
Keating,MJ;Kantarjian,H;Talpaz,M;Redman,J;Koller,C;Barlogie,B;Velasquez,W;Plunkett,W;Freireich,EJ;McCredie,KB
通讯作者：
McCredie,KB
DOI：
10.1200/jco.1991.9.5.770
发表时间：
1991-05
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
B. Raphael;Janet Andersen;R. Silber;Martin M. Oken;D. Moore;J. Bennett;H. Bonner;Richard G. Hahn;W. Knospe;Joseph J. Mazza
通讯作者：
B. Raphael;Janet Andersen;R. Silber;Martin M. Oken;D. Moore;J. Bennett;H. Bonner;Richard G. Hahn;W. Knospe;Joseph J. Mazza
脱氧考福霉素治疗患者外周血中 CD4 T 细胞恢复的动力学。
DOI：
10.1093/jnci/83.22.1678
发表时间：
1991
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Steis,RG;Urba,WJ;Kopp,WC;Alvord,WG;Smith2nd,JW;Longo,DL
通讯作者：
Longo,DL
2-氯脱氧腺苷：治疗慢性淋巴细胞白血病的有效新药。
影响因子：
20.3
作者：
Piro,LD;Carrera,CJ;Beutler,E;Carson,DA
通讯作者：
Carson,DA